Traditionally, myocardium reversibly injured by an episode of ischemia was thought to be more vulnerable to the effects of a subsequent episode; an extension of this view was that brief repeated ischemic episodes might cumulatively cause infarction. Multiple studies have now shown that this is not the case. Paradoxically, brief episodes of ischemia increase the heart's tolerance to a subsequent sustained period of ischemia, such that the rate of cell death is slowed substantially. Induction of tolerance in this manner has been termed ischemic preconditioning.1 In the current issue of Circulation, Liu et a12 have provided new evidence for a role for adenosine in mediating this ischemic tolerance. In this editorial comment we shall review what is known about the basic biology of preconditioning and its potential mechanisms, including the adenosine hypothesis, and address what is unknown and in need of future study.
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General Biology of Preconditioning Preconditioning was first performed in a canine model, using four 5-minute coronary occlusions interspersed with 5-minute reperfusion periods.1 However, preconditioning can be induced with a variety of protocols and in multiple species. Single occlusions of 53 or 154 minutes have been used to successfully precondition myocardium in dogs, and two 2-minute occlusions or one 5-minute occlusion is sufficient to precondition rabbit myocardium.5 Preconditioning has also been induced by two 10-minute occlusions in pigs.6 Although all models have shown dramatic infarct size limitation, there may be significant biological differences among them; one must therefore The opinions expressed in this editorial comment are not necessarily those of the editors or of the American Heart Association.
From A recent study provides evidence that preconditioning may occur in humans with coronary artery disease. Deutsch et a17 reported the effects of two sequential 90-second coronary occlusions, separated by 5 minutes of reperfusion, in 12 patients undergoing elective angioplasty of the left anterior descending coronary artery. The second episode of ischemia caused less chest pain, less ST segment elevation, and less myocardial lactate production. These changes were associated with reduced blood flow from the accompanying cardiac vein during the second occlusion. This suggests that the apparently less severe ischemia was not due to increased collateral blood flow, but rather reflected an adaptation of the myocardium to ischemia.
Initial studies in dogs demonstrated that preconditioning dramatically limited the size of infarcts resulting from 40 minutes of sustained ischemia. However, when the duration of the sustained ischemic episode was extended to 3 hours the effect was lost, and infarct size was not different between groups.' Subsequent studies have resolved further the duration of ischemia over which preconditioning is protective, demonstrating infarct size limitation after 60 but not 90 minutes of sustained ischemia.8 Thus, although the protective effect is dramatic in the early phases of ischemia, it clearly wanes significantly as the period of ischemia is extended past 60 minutes.
If the time between preconditioning and the subsequent sustained occlusion is prolonged, the protective effect is gradually lost. However, the time course for loss of preconditioning has not been well defined. Canine studies using a single 15-minute preconditioning occlusion showed dramatic infarct size limitation with only 5 minutes of intervening reperfusion (infarct size 8% of control), which was significantly attenuated after 120 minutes of reperfusion (46% of control).4 Miura et al,9 using a single 5-minute preconditioning occlusion in rabbits, have recently reported significant loss of protection after 25-35 minutes of intervening reperfusion. However, Schott et a16 reported marked protection in a pig model when 30 minutes of intervening reperfusion followed two 10-minute occlusions. Thus, the time course for the decay of ischemic tolerance may vary depending on the species and the particular protocol used to induce it. Within a given species, preconditioning protocols that cause more severe reversible injury may protect the myocardium for longer periods of ischemia, or their effects may decay more slowly during reperfusion; however, this has not been tested.
Histological studies have shown that preconditioning preserves the viability of both the myocytes and the microvasculature of the myocardium.1 Additionally, Miyazaki and Zipes10 have shown that preconditioning preserves the function of efferent sympathetic and parasympathetic nerve fibers that traverse an ischemic region. This autonomic preservation persisted through 3 hours of ischemia, despite apparently equivalent ultimate infarct sizes in preconditioned and control dogs.
The effects of preconditioning on myocardial arrhythmias have begun to be explored. Shiki and Hearse11 compared the incidence of reperfusion arrhythmias following sequential 5-minute coronary occlusions in rats. Reperfusion arrhythmias were common after the first occlusion but rare after the second, when the occlusions were separated by 10-60 minutes of reperfusion. Extending the duration of intervening reperfusion to 120 minutes or more increased the incidence of reflow arrhythmias after the second occlusion. Hagar et al12 used shorter preconditioning occlusions (three 2-minute occlusions) that did not cause arrhythmias themselves but markedly limited arrhythmias after a subsequent 5-minute coronary occlusion in rats. Studies of repeated coronary occlusions in dogs have been less conclusive. It has been well established that repeated coronary occlusions result in reduced susceptibility to ventricular fibrillation during subsequent episodes of ischemia; that is, they raise the ventricular fibrillation threshold.'3"14 However, repeated short occlusions have no effect on ventricular fibrillation threshold during the early phase of reperfusion. We have previously reported very high incidences of lethal arrhythmias after repeated 10-minute occlusions of the circumflex artery in dogs,1"'5 although the experiments were not designed to study arrhythmias directly. Thus, there is agreement that preconditioning attenuates reperfusion arrhythmias in the rat, but current evidence does not support such an effect in the dog. Although significant differences may exist between rat and dog models, this determination must await better definition of the effect of preconditioning on arrhythmias, particularly in dogs.
Potential Mechanisms
A myriad of potential mechanisms for the genesis of preconditioning have been proposed. Although the mechanism is not yet known, some important hypotheses have recently come under test. One potential explanation for protection is an increase in collateral blood flow. However, we have shown that one to four brief coronary occlusions do not increase collateral blood flow, or at least not over the time frame of our previous experiments.14"6 This is in contrast to chronic experimental models that use hundreds to thousands of occlusions over many days to weeks to induce collateral growth.17 Additional evidence against the collateral flow hypothesis comes from induction of preconditioning in rabbits and pigs, species that have little native collateral blood flow. Thus, increases in oxygen supply or catabolite washout during ischemia are unlikely to be responsible.
On the other hand, preconditioning markedly slows energy metabolism during ischemia. 16 Although some ATP is lost during preconditioning per se (resulting in production of adenosine and other purine nucleosides and bases), a slower rate of ATP depletion occurs during the subsequent ischemic episode, which in our studies resulted in transiently higher ATP levels in the preconditioned hearts. Glycogenolysis and anaerobic glycolysis occur much more slowly, with the result that accumulation of ischemic catabolites in the tissue is substantially reduced. We think it is likely that the slower ATP depletion and the reduced glycolytic rate are both manifestations of a reduction in energy demand during ischemia. The relative roles of preservation of ATP or limitation of catabolite accumulation in preserving cell viability have not yet been determined. A detailed discussion of how these metabolic changes may preserve viability is beyond the scope of this editorial. The interested reader is referred to Reference 16.
A reduction in energy demand implies that the activity of one or more ATP-consuming reactions is reduced. Furthermore, any such reaction must be relatively nonessential, because its absence is associated with increased cell viability. Efforts are underway in several laboratories to uncover the identity of this pathway. However, identification of candidates is hindered by the fact that the reactions that utilize ATP in control ischemic myocardium are poorly defined. The hypothesis most extensively tested is that energy demand is reduced by mechanical dysfunction (stunning), which occurs during preconditioning. If this is true, then recovery of function should occur in parallel with decay of protection, as the duration of reperfusion between occlusions is extended. However, extending the intervening reperfusion period to 2 hours significantly attenuates preconditioning without improving mechanical function.4 Along similar lines, Miura et a15 have reported a poor correlation between the extent of stunning and the amount of infarct size limitation by preconditioning. Schott et a16 reported a poor correlation between myocardial oxygen consumption prior to the sustained ischemic episode and the extent of protection subsequently afforded by preconditioning. Thus, it seems that stunning alone is insufficient to cause preconditioning. However, it should be noted that the converse experiment, testing whether preconditioning can occur in the absence of stunning, has not to our knowledge been performed.
Mitochondria have recently been identified as a major site of ATP utilization during ischemia.'8 Under hypoxic conditions the mitochondrial ATP synthetase complex functions in reverse, serving as an ATP hydrolyzing system. Inhibition of the mitochondrial ATPase with oligomycin results in substantial slowing of the rate of ATP depletion during ischemia. There also is an intramitochondrial inhibitor protein for the ATPase that binds to it under acidic conditions such as ischemia, when the mitochondria have become de-energized.19 It is possible, though unproven, that preconditioning is associated with persistent binding of the inhibitor, or causes this ATPase to be inhibited more rapidly during ischemia, and thereby slows the rate of ATP utilization. 20 Exposure of mammalian cells to a variety of stresses, including ischemia, results in synthesis of a family of related proteins termed stress or "heat shock" proteins. Although the function of these proteins is poorly understood, they have been associated with increased tolerance to subsequent episodes of stress. Furthermore, whole body heat shock has been reported to increase ischemic tolerance 24 hours later in rat21 and rabbit22 hearts. Thus, one explanation proposed for preconditioning has been the synthesis of one or more protective proteins. Indeed, recent studies have shown that brief coronary occlusions result in rapid transcription of mRNA for heat shock protein 70 as well as the proto-oncogene c-foS23,24; increases in translated heat shock protein 70 have been detected within 2 hours of short coronary occlusions.23 However, Thornton et a125 recently reported that inhibition of protein synthesis with cycloheximide or inhibition of mRNA transcription with actinomycin D does not attenuate preconditioning in rabbits. Using a converse approach, Schott et a126 demonstrated that induction of heat shock (and heat shock protein mRNA transcription) in porcine myocardium does not limit infarct size when coronary occlusion occurs shortly after this "thermal preconditioning"; however, it was not determined whether synthesis of heat shock proteins occurred over the relatively short time frame. Therefore, current evidence does not support a role for stress protein synthesis in preconditioning. However, the finding that reversible ischemic injury alters cardiac gene expression represents an important new area for future research.
Another aspect of reversible injury that could contribute to ischemic tolerance is production of oxygen-derived free radicals. It is well documented that brief coronary occlusions result in a burst of free radical production during reperfusion, which likely contributes to other aspects of reversible injury such as stunning and increased vascular permeability.27 '28 It is possible that in the setting of multiple coronary occlusions, free radicals could, paradoxically, be protective, for example by inhibiting the activity of biochemical pathways that "squander" ATP. However, studies testing this hypothesis have been conflicting. Initial studies from our laboratory provided some evidence for a role of free radicals.29 Administration of the free radical scavengers superoxide dismutase and catalase attenuated the effects of preconditioning in about 50% of animals, while no effect was observed in the other 50%; the reason for this nonuniform effect is unknown. Against this hypothesis is a recent report from Iwamoto et a130 that indicates no effect of free radical scavengers on preconditioning in rabbits. Further studies will be required to resolve these discrepancies.
In the current issue of Circulation, Liu et a12 have addressed the potential role of the purine nucleoside adenosine in mediating preconditioning. Utilizing both in situ and isolated blood-perfused rabbit hearts, they evaluated the effects of adenosine receptor antagonists and agonists on infarct size in preconditioned and control hearts. In the intact animal studies, treatment with nonselective adenosine receptor antagonists (mixed A, and A2 effects) completely abolished the effect of preconditioning but had no effect on infarct size in controls. However, substituting intravenous adenosine for preconditioning did not replicate its protective effect. In the isolated heart studies, both adenosine and an A, receptor agonist were as effective as preconditioning in limiting infarct size. The failure of adenosine to limit infarct size in the intact animal models after intravenous administration may have been due to inadequate levels in the coronary circulation, because it is deaminated rapidly in the intravascular space.
If these studies are corroborated in other models, they will have provided a significant advance in our understanding of preconditioning. However, it is not clear at present how adenosine might exert such a dramatic protective effect. Proposed mechanisms include preservation of ATP by enhancement of glycolytic flux and inhibition of "reperfusion injury" by activated neutrophils. However, both mechanisms seem unlikely to be operative. The first explanation has been directly refuted; glycolytic flux is markedly slowed in ischemic preconditioned myocardium, as part of the overall reduction in metabolic activity. 16 Casting doubt on the second hypothesis are metabolic and ultrastructural observations demonstrating marked reductions in indexes of cell injury during ischemia, before the reperfusion period during which neutrophils have been proposed to act. 16 Other known effects of adenosine such as coronary vasodilation and slowing of heart rate and AV nodal conduction31 also seem unlikely. Further studies clearly will be required to determine both the role of adenosine in preconditioning and how it relates to our current paradigms of cell injury.
